{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-034585","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.813653+00:00","generated_at":"2026-05-25T05:52:05.161753+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CytomX Therapeutics 2024 revenue $138.1M (up 36% YoY); CX-2051 data expected 1H 2025; headcount cut 40%","bullets":["Revenue $138.1M for FY2024 vs $101.2M in FY2023 (+36%); cash and investments $100.6M vs $174.5M at year-end.","Lead program CX-2051 (EpCAM ADC) Phase 1a initial data in advanced CRC expected 1H 2025; dose escalation at 7th dose level.","CX-801 (IFN-alpha) Phase 1a translational data in melanoma expected 2H 2025; monotherapy dose exceeds approved peginterferon dose.","CX-904 (EGFR-CD3 TCE) development discontinued by mutual decision with Amgen.","January 2025 restructuring reduced headcount ~40% to extend cash runway into Q2 2026; Astellas milestone triggered $5M payment."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-034585","json":"https://secwatch.observer/filing/0000950170-25-034585.json","markdown":"https://secwatch.observer/filing/0000950170-25-034585.md","text":"https://secwatch.observer/filing/0000950170-25-034585.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000095017025034585/0000950170-25-034585-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000095017025034585/ctmx-20250306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T05:52:05.161753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}